Company / Operating Cash Flow
Vaxcyte, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$655.6M
FY2025
5-year range
-$655.6M / -$121.4M
FY2021-FY2025
Trend
-44.8%
vs FY2024
Sector context
#212 of 216
Health Care
What the data says
Among 216 Health Care companies, Vaxcyte, Inc. is in the bottom 2% for operating cash flow. Operating Cash Flow has declined for 5 consecutive years, from -$47M in FY2020 to -$656M in FY2025.
Based on SEC 10-K filings.
-$656M in FY2025.
Declined from -$297M to -$656M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 216This company -$655.6M Sector average $658.7M
▼
-199.5% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 44.8% year-over-year.
- Ranks #212 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$655.6M | -44.8% |
| FY2024 | -$452.6M | -52.5% |
| FY2023 | -$296.8M | -74.0% |
| FY2022 | -$170.6M | -40.5% |
| FY2021 | -$121.4M | -160.3% |
| FY2020 | -$46.6M | +1.1% |
| FY2019 | -$47.1M | -54.7% |
| FY2018 | -$30.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026